Editor’s Note
**Editor’s Note:** Hugel has introduced ‘TheCharm Signature’, a new HA filler line designed to improve safety by reducing crosslinking agents. The four-product range offers varied physical properties for tailored clinical use.
Hugel has launched a new hyaluronic acid (HA) filler product, ‘TheCharm Signature’, on the 20th, which enhances safety by minimizing the use of crosslinking agents.
TheCharm Signature is a product line reflecting Hugel’s HA filler R&D achievements, consisting of four types with a spectrum of physical properties, allowing medical professionals to choose according to the treatment area and purpose.
HA fillers typically undergo a crosslinking process to maintain easily degradable hyaluronic acid in a stable gel form.
TheCharm Signature applies the MPC (Multi Purified Crosslinking) technology, a proprietary technique of its affiliate Across, reducing the amount of crosslinking agent used by over 50% compared to conventional manufacturing processes. It also increases crosslinking efficiency through a special process using high-concentration HA raw materials.
According to Hugel, the product undergoes a multi-purification process lasting approximately two weeks, longer than standard processes, to reduce residual crosslinking agent (BDDE) and micro-hydrolysis byproducts (BDPE) that can occur during the crosslinking stage. The company explains that despite minimizing the use of crosslinking agents, the physical properties and durability of the existing ‘TheCharm Premium’ line are maintained.